NCT04392362 (AHAvsSIM) is a Phase 3 clinical trial of Adenosine in Supra-ventricular Tachycardia, sponsored by University of Pretoria.

Who is sponsoring NCT04392362?

NCT04392362 is sponsored by University of Pretoria.

What drugs are being tested in NCT04392362?

Interventions in NCT04392362: Adenosine.

What condition does NCT04392362 study?

NCT04392362 studies Supra-ventricular Tachycardia.

Is NCT04392362 still recruiting?

NCT04392362 is currently completed. Last updated 25 June 2021.

Are results published for NCT04392362?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-06-25 · How we verify

NCT04392362: AHAvsSIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)

Completed Phase 3 Results posted Last updated 25 June 2021

What this trial tests

Phase 3 trial testing Adenosine in Supra-ventricular Tachycardia in 30 participants. Completed in 16 December 2020.

Timeline

1 April 2018

Primary endpoint
16 December 2020

16 December 2020

Quick facts

Lead sponsor	University of Pretoria
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 April 2018
Primary completion	16 December 2020
Estimated completion	16 December 2020
Sites	1 location across South Africa

Drugs / interventions tested

Adenosine (ADENOSINE) — full drug profile →

Conditions studied

Supra-ventricular Tachycardia — all drugs for Supra-ventricular Tachycardia →

Sponsor

University of Pretoria

Who can join

Adults 18 to 80, any sex, with Supra-ventricular Tachycardia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Number of Patients With First Dose Successful Termination of the Supraventricular Tachycardia to a Sinus Rhythm of Less Than 140 With the AHA Versus a Simplified Method of Adenosine Administration Primary · 10 seconds

The primary outcome is the rhythm of conversion to a sinus rhythm less than 140 beat per minute.

Group	Value	95% CI
Intervention Group	13
Control Group	4

Adverse events — posted to ClinicalTrials.gov

Time frame: 2 hours. Reporting threshold: 1%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Intervention Group

Serious: 0/23 (0%)

Deaths: 0/23

Control Group

Serious: 0/7 (0%)

Deaths: 0/7

Other adverse events (1 terms — click to expand)

Reaction	System	Intervention Group	Control Group
Feeling of impending doom, dizziness	Cardiac disorders	—	—

Data from ClinicalTrials.gov NCT04392362 adverse events section.

Sponsor's own description

Study to compare non inferiority of giving adenosine with the simplified method vs the AHA method

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The impact of purine nucleosides on neuroplasticity in the adult brain.
Dos Santos B, Piermartiri T, Tasca CI. · · 2025 · cited 4× · PMID 38367178 · DOI 10.1007/s11302-024-09988-9

Verify or expand the search:

Other trials of Adenosine

Trials testing the same drug.

NCT06717685 — Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients · Phase 3 · recruiting
NCT06578234 — Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses · Phase 4 · recruiting
NCT04699110 — Adrenaline for the Treatment of No-Reflow in Normotensive Patients · Phase 4 · completed
NCT04577443 — The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties. · NA · completed
NCT03738943 — Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults · EARLY_PHASE1 · completed

Other University of Pretoria trials

Trials by the same sponsor.

NCT06982716 — Evaluating the Clinical Effectiveness of a Community-based Hearing Aid Fitting Service Delivery Model Facilitated by Com · NA · recruiting
NCT06487767 — The Validity of the Use of Imaging in Cervical Cancer Staging · not yet recruiting
NCT04792710 — Kefazolin Versus Kefazolin Plus Metronidazole to Reduce Postpartum Infection · Phase 4 · unknown
NCT05632705 — Efficacy of Using a Closing Pack to Reduce Postpartum Sepsis · NA · completed
NCT02750202 — Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04392362 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pretoria
Last refreshed: 25 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04392362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing